We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

XYL:NYSEXylem Inc. Analysis

Data as of 2026-09-02 - not real-time

$106.89

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

At $106.89, Xylem Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Across the trailing 30 sessions it lost 8.6%. Relative strength is 29.6 — oversold — and the MACD signal is bearish. The recent range runs from support at $106.59 up to resistance at $124.00.
Multiples put this in undervalued territory: 25.4 times earnings against the sector's 28.6. Consensus targets land 44.0% above where the shares trade now. The 1.61% dividend yield looks covered by current payout levels.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 29.3%, a beta of 0.81 and a maximum drawdown of 30.5%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 4/10 long-term conviction.

Top Market Events

What Happened? Shares of water technology company Xylem NYSE:XYL jumped 4.4% in the morning session after the company...Xylem beat adjusted earnings by 9% and lifted full-year profit guidance on surging orders of $3.Water technology company Xylem NYSE:XYL met Wall Street’s revenue expectations in Q2 CY2026, with sales up 1.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.6 signals oversold conditions
  • Trading below the 200-day average of 124.80

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • RSI at 29.6 signals oversold conditions
  • P/E of 25.4 versus sector average of 28.6

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 25.4 versus sector average of 28.6
  • Analyst targets imply +44.0% versus the current price
  • Dividend yield of 1.61%

Key Metrics & Analysis

Financial Health

Revenue Growth1.50%
Profit Margin11.15%
P/E Ratio25.4
ROE9.18%
ROA5.11%
Debt/Equity28.64
P/B Ratio2.3
Op. Cash Flow$1.3B
Free Cash Flow$1.2B
Industry P/E28.6

Technical Analysis

TrendBearish
RSI29.6
Support$106.59
Resistance$124.00
MA 20$116.27
MA 50$117.91
MA 200$124.80
MACDBearish
VolumeIncreasing
Fear & Greed Index92.57

Valuation

Fair Value$61.05
Target Price$153.88
Upside/Downside43.96%
GradeUndervalued
TypeBlend
Dividend Yield1.61%

Risk Assessment

Beta0.81
Volatility29.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.